Abstract
In high-grade AOC patients, the combination of immunotherapy, PARP inhibitors (PARPi), and antiangiogenic agents, may enhance the efficacy of each treatment. Different chemotherapy-free combinations were previously found to be feasible. A significant activity of the Durva + Ola +/- Bev combination was reported in platinum-sensitive recurrent (PSR) AOC in the MEDIOLA trial. However the efficacy of the triplet in platinum resistant relapse (PRR) has never been assessed.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
